{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T22:49:36Z","timestamp":1782514176945,"version":"3.54.5"},"reference-count":120,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1053\/j.ajkd.2025.11.021","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T15:04:00Z","timestamp":1774883040000},"page":"127-141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Complement 3 Glomerulopathy (C3G) in Native and Posttransplant Kidneys: A Review"],"prefix":"10.1053","volume":"88","author":[{"given":"Manuel","family":"Praga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew S.","family":"Bomback","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1053\/j.ajkd.2025.11.021_bib1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1053\/j.akdh.2024.05.002","article-title":"Update on C3 glomerulopathy","volume":"31","author":"Wooden","year":"2024","journal-title":"Adv Kidney Dis Health"},{"issue":"3","key":"10.1053\/j.ajkd.2025.11.021_bib2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41581-018-0107-2","article-title":"C3 glomerulopathy \u2013 understanding a rare complement-driven renal disease","volume":"15","author":"Smith","year":"2019","journal-title":"Nat Rev Nephrol"},{"issue":"8","key":"10.1053\/j.ajkd.2025.11.021_bib3","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/nrneph.2010.85","article-title":"C3 glomerulopathy: a new classification","volume":"6","author":"Fakhouri","year":"2010","journal-title":"Nat Rev Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2025.11.021_bib4","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/ki.2012.80","article-title":"C3 glomerulopathy: what\u2019s in a name?","volume":"82","author":"D\u2019Agati","year":"2012","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.ajkd.2025.11.021_bib5","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/ki.2013.377","article-title":"C3 glomerulopathy: consensus report","volume":"84","author":"Pickering","year":"2013","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.ajkd.2025.11.021_bib6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000524552","article-title":"C3 glomerulopathy: a review with emphasis on ultrastructural features","volume":"2","author":"Hou","year":"2022","journal-title":"Glomerular Dis"},{"issue":"5","key":"10.1053\/j.ajkd.2025.11.021_bib7","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.kint.2024.02.013","article-title":"Apolipoprotein E is enriched in dense deposits and is a marker for dense deposit disease in C3 glomerulopathy","volume":"105","author":"Madden","year":"2024","journal-title":"Kidney Int"},{"issue":"12","key":"10.1053\/j.ajkd.2025.11.021_bib8","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMra1108178","article-title":"Membranoproliferative glomerulonephritis\u2014a new look at an old entity","volume":"366","author":"Sethi","year":"2012","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1053\/j.ajkd.2025.11.021_bib9","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.2215\/CJN.01710216","article-title":"All things complement","volume":"11","author":"Thurman","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2025.11.021_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fneph.2024.1460146","article-title":"C3 glomerulopathy: a kidney disease mediated by alternative pathway deregulation","volume":"4","author":"Heidenreich","year":"2024","journal-title":"Front Nephrol"},{"key":"10.1053\/j.ajkd.2025.11.021_bib11","series-title":"GeneReviews [Internet]","article-title":"C3 glomerulopathy","author":"Martin","year":"2007"},{"issue":"3","key":"10.1053\/j.ajkd.2025.11.021_bib12","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) controversies conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int"},{"issue":"4 suppl","key":"10.1053\/j.ajkd.2025.11.021_bib13","first-page":"S1","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"issue":"8","key":"10.1053\/j.ajkd.2025.11.021_bib14","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.2215\/CJN.0000000000000474","article-title":"C3 glomerulopathy recurs early after kidney transplantation in serial biopsies performed within the first 2 years post-transplantation","volume":"19","author":"Tarrag\u00f3n","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2025.11.021_bib15","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/ndt\/gfab281","article-title":"Membranoproliferative glomerulonephritis: no longer the same disease and may need very different treatment","volume":"38","author":"Noris","year":"2023","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1053\/j.ajkd.2025.11.021_bib16","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/cr.2009.139","article-title":"Complement and its role in innate and adaptive immune responses","volume":"20","author":"Dunkelberger","year":"2010","journal-title":"Cell Res"},{"issue":"12","key":"10.1053\/j.ajkd.2025.11.021_bib17","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/s41581-023-00766-1","article-title":"The role of complement in kidney disease","volume":"19","author":"Petr","year":"2023","journal-title":"Nat Rev Nephrol"},{"issue":"8","key":"10.1053\/j.ajkd.2025.11.021_bib18","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.4049\/jimmunol.1203487","article-title":"Complement in immune and inflammatory disorders: pathophysiological mechanisms","volume":"190","author":"Ricklin","year":"2013","journal-title":"J Immunol"},{"key":"10.1053\/j.ajkd.2025.11.021_bib19","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.3389\/fimmu.2019.01308","article-title":"Complement nomenclature-deconvoluted","volume":"10","author":"Bohlson","year":"2019","journal-title":"Front Immunol"},{"key":"10.1053\/j.ajkd.2025.11.021_bib20","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3389\/fimmu.2015.00262","article-title":"Complement system part I - molecular mechanisms of activation and regulation","volume":"6","author":"Merle","year":"2015","journal-title":"Front Immunol"},{"key":"10.1053\/j.ajkd.2025.11.021_bib21","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12915-015-0203-8","article-title":"Molecular insights into the surface-specific arrangement of complement C5 convertase enzymes","volume":"13","author":"Berends","year":"2015","journal-title":"BMC Biol"},{"issue":"1","key":"10.1053\/j.ajkd.2025.11.021_bib22","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/imr.13166","article-title":"The factor H protein family: the switchers of the complement alternative pathway","volume":"313","author":"Lucientes-Continente","year":"2023","journal-title":"Immunol Rev"},{"issue":"3","key":"10.1053\/j.ajkd.2025.11.021_bib23","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10238-018-0491-8","article-title":"The role of the alternative pathway of complement activation in glomerular diseases","volume":"18","author":"Lukawska","year":"2018","journal-title":"Clin Exp Med"},{"issue":"6","key":"10.1053\/j.ajkd.2025.11.021_bib24","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1159\/000507254","article-title":"Update on C3 glomerulopathy: a complement-mediated disease","volume":"144","author":"Caravaca-Font\u00e1n","year":"2020","journal-title":"Nephron"},{"issue":"1","key":"10.1053\/j.ajkd.2025.11.021_bib25","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ekir.2024.09.017","article-title":"Challenges in the diagnosis and management of immune complex-mediated membranoproliferative glomerulonephritis and complement 3 glomerulopathy","volume":"10","author":"Bomback","year":"2025","journal-title":"Kidney Int Rep"},{"issue":"4","key":"10.1053\/j.ajkd.2025.11.021_bib26","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/ki.2012.63","article-title":"Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies","volume":"82","author":"Servais","year":"2012","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2025.11.021_bib27","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.molimm.2016.01.010","article-title":"Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome","volume":"71","author":"Iatropoulos","year":"2016","journal-title":"Mol Immunol"},{"issue":"4","key":"10.1053\/j.ajkd.2025.11.021_bib28","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.kint.2017.10.022","article-title":"C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy","volume":"93","author":"Bomback","year":"2018","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2025.11.021_bib29","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1681\/ASN.2017030258","article-title":"Cluster analysis identifies distinct pathogenetic patterns in C3 glomerulopathies\/immune complex-mediated membranoproliferative GN","volume":"29","author":"Iatropoulos","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"10.1053\/j.ajkd.2025.11.021_bib30","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.mayocp.2018.05.019","article-title":"C3 glomerulopathy: ten years\u2019 experience at Mayo Clinic","volume":"93","author":"Ravindran","year":"2018","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1053\/j.ajkd.2025.11.021_bib31","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1186\/s13023-019-1237-8","article-title":"C4 nephritic factor in patients with immune-complex-mediated membranoproliferative glomerulonephritis and C3-glomerulopathy","volume":"14","author":"Garam","year":"2019","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"10.1053\/j.ajkd.2025.11.021_bib32","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/ckj\/sfz073","article-title":"Validation of distinct pathogenic patterns in a cohort of membranoproliferative glomerulonephritis patients by cluster analysis","volume":"13","author":"Garam","year":"2020","journal-title":"Clin Kidney J"},{"issue":"5","key":"10.1053\/j.ajkd.2025.11.021_bib33","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.kint.2017.04.017","article-title":"C5 nephritic factors drive the biological phenotype of C3 glomerulopathies","volume":"92","author":"Marinozzi","year":"2017","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.ajkd.2025.11.021_bib34","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1681\/ASN.2016030343","article-title":"Anti-factor B and anti-C3b autoantibodies in C3 glomerulopathy and Ig-associated membranoproliferative GN","volume":"28","author":"Marinozzi","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2025.11.021_bib35","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.kint.2018.01.037","article-title":"C3 glomerulopathy associated with monoclonal Ig is a distinct subtype","volume":"94","author":"Ravindran","year":"2018","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.ajkd.2025.11.021_bib36","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3390\/cells12050712","article-title":"Diagnostic and prognostic comparison of immune-complex-mediated membranoproliferative glomerulonephritis and C3 glomerulopathy","volume":"12","author":"Kovala","year":"2023","journal-title":"Cells"},{"key":"10.1053\/j.ajkd.2025.11.021_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1036136","article-title":"Challenges in diagnostic testing of nephritic factors","volume":"13","author":"Michels","year":"2022","journal-title":"Front Immunol"},{"issue":"2","key":"10.1053\/j.ajkd.2025.11.021_bib38","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ekir.2023.11.025","article-title":"Defining nephritic factors as diverse drivers of systemic complement dysregulation in C3 glomerulopathy","volume":"9","author":"Hauer","year":"2024","journal-title":"Kidney Int Rep"},{"issue":"11","key":"10.1053\/j.ajkd.2025.11.021_bib39","doi-asserted-by":"crossref","first-page":"5129","DOI":"10.4049\/jimmunol.1402770","article-title":"Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases","volume":"194","author":"Blanc","year":"2015","journal-title":"J Immunol"},{"issue":"5","key":"10.1053\/j.ajkd.2025.11.021_bib40","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.kint.2020.05.053","article-title":"Practical management of C3 glomerulopathy and Ig-mediated MPGN: facts and uncertainties","volume":"98","author":"Fakhouri","year":"2020","journal-title":"Kidney Int"},{"issue":"9","key":"10.1053\/j.ajkd.2025.11.021_bib41","doi-asserted-by":"crossref","first-page":"8432","DOI":"10.3390\/ijms24098432","article-title":"Clinico-pathogenic similarities and differences between infection-related glomerulonephritis and C3 glomerulopathy","volume":"24","author":"Wada","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"20","key":"10.1053\/j.ajkd.2025.11.021_bib42","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1056\/NEJMra1810907","article-title":"Monoclonal gammopathy of renal significance","volume":"384","author":"Leung","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ajkd.2025.11.021_bib43","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.3389\/fimmu.2018.02260","article-title":"Both monoclonal and polyclonal immunoglobulin contingents mediate complement activation in monoclonal gammopathy associated-C3 glomerulopathy","volume":"9","author":"Chauvet","year":"2018","journal-title":"Front Immunol"},{"issue":"2","key":"10.1053\/j.ajkd.2025.11.021_bib44","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/ki.2012.384","article-title":"Atypical post-infectious glomerulonephritis is associated with abnormalities in the alternative pathway of complement","volume":"83","author":"Sethi","year":"2013","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ajkd.2025.11.021_bib45","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1159\/000515461","article-title":"Infection-related glomerulonephritis","volume":"1","author":"Khalighi","year":"2021","journal-title":"Glomerular Dis"},{"issue":"3","key":"10.1053\/j.ajkd.2025.11.021_bib46","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/ckj\/sfw032","article-title":"Revisiting post-infectious glomerulonephritis in the emerging era of C3 glomerulopathy","volume":"9","author":"Khalighi","year":"2016","journal-title":"Clin Kidney J"},{"issue":"3","key":"10.1053\/j.ajkd.2025.11.021_bib47","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1053\/j.ajkd.2013.02.370","article-title":"C3 glomerulonephritis associated with monoclonal gammopathy: a case series","volume":"62","author":"Zand","year":"2013","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1053\/j.ajkd.2025.11.021_bib48","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.kint.2024.05.015","article-title":"The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference","volume":"106","author":"Vivarelli","year":"2024","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2025.11.021_bib49","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/imr.13168","article-title":"The susceptibility of the kidney to alternative pathway activation-a hypothesis","volume":"313","author":"Thurman","year":"2023","journal-title":"Immunol Rev"},{"issue":"4","key":"10.1053\/j.ajkd.2025.11.021_bib50","doi-asserted-by":"crossref","first-page":"632","DOI":"10.5500\/wjt.v6.i4.632","article-title":"Complement related kidney diseases: recurrence after transplantation","volume":"6","author":"Salvadori","year":"2016","journal-title":"World J Transplant"},{"issue":"2","key":"10.1053\/j.ajkd.2025.11.021_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.trre.2024.100839","article-title":"Recurrent C3 glomerulopathy after kidney transplantation","volume":"38","author":"Obata","year":"2024","journal-title":"Transplant Rev (Orlando)"},{"issue":"3","key":"10.1053\/j.ajkd.2025.11.021_bib52","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.kint.2025.06.003","article-title":"Quantifying association of early proteinuria and estimated glomerular filtration rate changes with long-term kidney failure in C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis using the United Kingdom RaDaR Registry","volume":"108","author":"Masoud","year":"2025","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2025.11.021_bib53","doi-asserted-by":"crossref","first-page":"46","DOI":"10.2215\/CJN.04700513","article-title":"C3 glomerulopathy: clinicopathologic features and predictors of outcome","volume":"9","author":"Medjeral-Thomas","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2025.11.021_bib54","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2215\/CJN.03480708","article-title":"Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients","volume":"4","author":"Nasr","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"suppl 1","key":"10.1053\/j.ajkd.2025.11.021_bib55","first-page":"1196","article-title":"C3G and ic-MPGN across the life span: findings from the European Rare Kidney Disease Registry","volume":"39","author":"Schaefer","year":"2024","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1053\/j.ajkd.2025.11.021_bib56","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.kint.2022.05.027","article-title":"Results from a nationwide retrospective cohort measure the impact of C3 and soluble C5b-9 levels on kidney outcomes in C3 glomerulopathy","volume":"102","author":"Chauvet","year":"2022","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.ajkd.2025.11.021_bib57","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00467-020-04768-0","article-title":"Pediatric C3 glomerulopathy: a 12-year single-center experience","volume":"36","author":"Zahir","year":"2021","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2025.11.021_bib58","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00467-020-04736-8","article-title":"Therapy and outcomes of C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis","volume":"36","author":"Khandelwal","year":"2021","journal-title":"Pediatr Nephrol"},{"issue":"7","key":"10.1053\/j.ajkd.2025.11.021_bib59","doi-asserted-by":"crossref","first-page":"994","DOI":"10.2215\/CJN.16801221","article-title":"Association of histologic parameters with outcome in C3 glomerulopathy and idiopathic immunoglobulin-associated membranoproliferative glomerulonephritis","volume":"17","author":"Lomax-Browne","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"10.1053\/j.ajkd.2025.11.021_bib60","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.2215\/CJN.15241219","article-title":"Mycophenolate mofetil in C3 glomerulopathy and pathogenic drivers of the disease","volume":"15","author":"Caravaca-Font\u00e1n","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2025.11.021_bib61","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000479012","article-title":"Immunosuppressive treatment in C3 glomerulopathy: is it really effective?","volume":"46","author":"Caliskan","year":"2017","journal-title":"Am J Nephrol"},{"issue":"11","key":"10.1053\/j.ajkd.2025.11.021_bib62","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1093\/ndt\/gfab169","article-title":"Contribution of a histologic index to the prognostic information of C3 glomerulopathy","volume":"36","author":"Caravaca-Font\u00e1n","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1053\/j.ajkd.2025.11.021_bib63","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1053\/j.ajkd.2020.11.011","article-title":"Validation of a histologic scoring index for C3 glomerulopathy","volume":"77","author":"Caravaca-Font\u00e1n","year":"2021","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"10.1053\/j.ajkd.2025.11.021_bib64","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/ndt\/gfab075","article-title":"Longitudinal change in proteinuria and kidney outcomes in C3 glomerulopathy","volume":"37","author":"Caravaca-Font\u00e1n","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1053\/j.ajkd.2025.11.021_bib65","doi-asserted-by":"crossref","first-page":"659","DOI":"10.34067\/KID.0000000000000115","article-title":"Clinical profiles and patterns of kidney disease progression in C3 glomerulopathy","volume":"4","author":"Caravaca-Font\u00e1n","year":"2023","journal-title":"Kidney360"},{"key":"10.1053\/j.ajkd.2025.11.021_bib66","series-title":"Voice of the patient: report of externally-led patient-focused drug development meeting on: complement 3 glomerulopathy (C3G)","author":"Feldman","year":"2018"},{"issue":"suppl","key":"10.1053\/j.ajkd.2025.11.021_bib67","first-page":"272","article-title":"Real-world time to diagnosis in c3 glomerulopathy (C3G)","volume":"11","author":"Lafayette","year":"2023","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"10.1053\/j.ajkd.2025.11.021_bib68","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.2215\/CJN.00320121","article-title":"C3 Glomerulopathy and related disorders in children: etiology-phenotype correlation and outcomes","volume":"16","author":"Wong","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"10.1053\/j.ajkd.2025.11.021_bib69","article-title":"Patterns of glomerular injury: histopathological classification and clinical correlation","volume":"17","author":"Qasim","year":"2025","journal-title":"Cureus"},{"issue":"suppl","key":"10.1053\/j.ajkd.2025.11.021_bib70","article-title":"CKD progression in patients with complement 3 glomerulopathy (C3G) in a US multi-center assessment","volume":"9","author":"Ndife","year":"2023","journal-title":"Kidney Int Rep"},{"issue":"8","key":"10.1053\/j.ajkd.2025.11.021_bib71","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1681\/ASN.0000000000000373","article-title":"Complement terminal pathway activation and intrarenal immune response in C3 glomerulopathy","volume":"35","author":"Meuleman","year":"2024","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"10.1053\/j.ajkd.2025.11.021_bib72","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.2215\/CJN.0000000000000252","article-title":"Rare variants in complement gene in C3 glomerulopathy and immunoglobulin-mediated membranoproliferative GN","volume":"18","author":"Meuleman","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2025.11.021_bib73","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1053\/j.ajkd.2018.09.002","article-title":"Kidney transplantation in C3 glomerulopathy: a case series","volume":"73","author":"Regunathan-Shenk","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"10.1053\/j.ajkd.2025.11.021_bib74","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1007\/s00467-024-06476-5","article-title":"Kidney transplantation in children and adolescents with C3 glomerulopathy or immune complex membranoproliferative glomerulonephritis: a real-world study within the CERTAIN research network","volume":"39","author":"Patry","year":"2024","journal-title":"Pediatr Nephrol"},{"issue":"8","key":"10.1053\/j.ajkd.2025.11.021_bib75","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/ki.2010.1","article-title":"Recurrent membranoproliferative glomerulonephritis after kidney transplantation","volume":"77","author":"Lorenz","year":"2010","journal-title":"Kidney Int"},{"issue":"11","key":"10.1053\/j.ajkd.2025.11.021_bib76","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1097\/TP.0b013e318218e94e","article-title":"Membranoproliferative glomerulonephritis type I in renal transplantation patients: a single-center study of a cohort of 68 renal transplants followed up for 11 years","volume":"91","author":"Moroni","year":"2011","journal-title":"Transplantation"},{"issue":"7","key":"10.1053\/j.ajkd.2025.11.021_bib77","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1681\/ASN.2005020175","article-title":"Recurrence of membranoproliferative glomerulonephritis type II in renal allografts: the North American Pediatric Renal Transplant Cooperative Study experience","volume":"16","author":"Braun","year":"2005","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2025.11.021_bib78","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/sj.ki.5000084","article-title":"Severity of primary MPGN, rather than MPGN type, determines renal survival and post-transplantation recurrence risk","volume":"69","author":"Little","year":"2006","journal-title":"Kidney Int"},{"issue":"10 suppl","key":"10.1053\/j.ajkd.2025.11.021_bib79","first-page":"SA","article-title":"Clinical burden of native vs post-transplant complement 3 glomerulopathy (C3G) in the United States (US): a retrospective claims analysis [abstract]","volume":"35","author":"Ndife","year":"2024","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2025.11.021_bib80","first-page":"44","article-title":"Treatment of C3 glomerulopathy in adult kidney transplant recipients: a systematic review","volume":"8","author":"Gonzalez Suarez","year":"2020","journal-title":"Med Sci (Basel)"},{"issue":"suppl 3","key":"10.1053\/j.ajkd.2025.11.021_bib81","first-page":"S1","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients","volume":"9","year":"2009","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1053\/j.ajkd.2025.11.021_bib82","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/ndt\/gfac148","article-title":"Recurrence of immune complex and complement-mediated membranoproliferative glomerulonephritis in kidney transplantation","volume":"38","author":"Caravaca-Font\u00e1n","year":"2023","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1053\/j.ajkd.2025.11.021_bib83","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfaf134","article-title":"Kidney transplant in patients with C3 glomerulopathy","volume":"18","author":"Attieh","year":"2025","journal-title":"Clin Kidney J"},{"issue":"12","key":"10.1053\/j.ajkd.2025.11.021_bib84","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfae320","article-title":"Post-transplant glomerular diseases: update on pathophysiology, risk factors and management strategies","volume":"17","author":"Regalia","year":"2024","journal-title":"Clin Kidney J"},{"issue":"3","key":"10.1053\/j.ajkd.2025.11.021_bib85","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ekir.2023.12.007","article-title":"C3 glomerulopathy: novel treatment paradigms","volume":"9","author":"Tarragon Estebanez","year":"2024","journal-title":"Kidney Int Rep"},{"issue":"11","key":"10.1053\/j.ajkd.2025.11.021_bib86","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1182\/blood-2016-08-737163","article-title":"Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy","volume":"129","author":"Chauvet","year":"2017","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.ajkd.2025.11.021_bib87","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1093\/ndt\/gfab302","article-title":"C3 glomerulopathy associated with monoclonal gammopathy: impact of chronic histologic lesions and beneficial effects of clone-targeted therapies","volume":"37","author":"Caravaca-Font\u00e1n","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1053\/j.ajkd.2025.11.021_bib88","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/ndt\/gfad175","article-title":"Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis","volume":"39","author":"Caravaca-Font\u00e1n","year":"2024","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1053\/j.ajkd.2025.11.021_bib89","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/ki.2015.227","article-title":"Effectiveness of mycophenolate mofetil in C3 glomerulonephritis","volume":"88","author":"Rabasco","year":"2015","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.ajkd.2025.11.021_bib90","doi-asserted-by":"crossref","first-page":"406","DOI":"10.2215\/CJN.09080817","article-title":"Mycophenolate mofetil in combination with steroids for treatment of C3 glomerulopathy: a case series","volume":"13","author":"Avasare","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"10.1053\/j.ajkd.2025.11.021_bib91","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.3390\/jpm13121706","article-title":"Adverse drug events after kidney transplantation","volume":"13","author":"Rostaing","year":"2023","journal-title":"J Pers Med"},{"issue":"5","key":"10.1053\/j.ajkd.2025.11.021_bib92","doi-asserted-by":"crossref","first-page":"748","DOI":"10.2215\/CJN.12901211","article-title":"Eculizumab for dense deposit disease and C3 glomerulonephritis","volume":"7","author":"Bomback","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2025.11.021_bib93","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12882-017-0802-4","article-title":"Treating C3 glomerulopathy with eculizumab","volume":"19","author":"Welte","year":"2018","journal-title":"BMC Nephrology"},{"issue":"1","key":"10.1053\/j.ajkd.2025.11.021_bib94","doi-asserted-by":"crossref","first-page":"51","DOI":"10.5414\/CN109890","article-title":"Eculizumab in post-transplant C3 glomerulonephritis caused by a C3 mutation","volume":"93","author":"Kim","year":"2020","journal-title":"Clin Nephrol"},{"issue":"10","key":"10.1053\/j.ajkd.2025.11.021_bib95","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1007\/s00467-013-2503-y","article-title":"Eculizumab and recurrent C3 glomerulonephritis","volume":"28","author":"Gurkan","year":"2013","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2025.11.021_bib96","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1681\/ASN.0000000526","article-title":"Safety and efficacy of avacopan in patients with complement 3 glomerulopathy: randomized, double-blind clinical trial","volume":"36","author":"Bomback","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2025.11.021_bib97","series-title":"Novartis Pharmaceuticals Corp","year":"2025"},{"key":"10.1053\/j.ajkd.2025.11.021_bib98","article-title":"FDA approves first treatment for adults with complement 3 glomerulopathy, a rare kidney disease, to reduce proteinuria","year":"2025","journal-title":"US Food and Drug Administration"},{"issue":"12","key":"10.1053\/j.ajkd.2025.11.021_bib99","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1016\/j.ekir.2023.09.017","article-title":"Efficacy and safety of iptacopan in patients with C3 glomerulopathy","volume":"8","author":"Wong","year":"2023","journal-title":"Kidney Int Rep"},{"issue":"2","key":"10.1053\/j.ajkd.2025.11.021_bib100","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ekir.2024.10.023","article-title":"Iptacopan reduces proteinuria and stabilizes kidney function in C3 glomerulopathy","volume":"10","author":"Nester","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1053\/j.ajkd.2025.11.021_bib101","series-title":"Efficacy and safety of iptacopan in patients with C3 glomerulopathy: results from the phase 3 APPEAR-C3G trial","author":"Kavanagh","year":"2024"},{"issue":"10 suppl","key":"10.1053\/j.ajkd.2025.11.021_bib102","first-page":"SA","article-title":"Efficacy and safety of iptacopan in patients with C3 glomerulopathy: 12-month results from the phase 3 APPEAR-C3G study [abstract]","volume":"35","author":"Nester","year":"2024","journal-title":"J Am Soc Nephrol"},{"issue":"10512","key":"10.1053\/j.ajkd.2025.11.021_bib103","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/S0140-6736(25)01148-1","article-title":"Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 study","volume":"406","author":"Kavanagh","year":"2025","journal-title":"Lancet"},{"issue":"6","key":"10.1053\/j.ajkd.2025.11.021_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2024.100823","article-title":"Factor B inhibition with iptacopan in recurrent C3 glomerulopathy following kidney transplant: a report of two cases","volume":"6","author":"Escudero-Saiz","year":"2024","journal-title":"Kidney Med"},{"issue":"10 suppl","key":"10.1053\/j.ajkd.2025.11.021_bib105","first-page":"SA","article-title":"Experience with iptacopan in patients with recurrent complement 3 glomerulopathy (C3G): early access program data [abstract]","volume":"35","author":"Smeets","year":"2024","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"10.1053\/j.ajkd.2025.11.021_bib106","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/j.ekir.2023.08.033","article-title":"Clinical safety and efficacy of pegcetacoplan in a phase 2 study of patients with C3 glomerulopathy and other complement-mediated glomerular diseases","volume":"8","author":"Dixon","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1053\/j.ajkd.2025.11.021_bib107","series-title":"FDA Approves Apellis\u2019 EMPAVELI\u00ae (pegcetacoplan) as the first C3G and primary IC-MPGN treatment for patients 12 and older","year":"2025"},{"issue":"1","key":"10.1053\/j.ajkd.2025.11.021_bib108","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ekir.2024.09.030","article-title":"Efficacy and safety of pegcetacoplan in kidney transplant recipients with recurrent complement 3 glomerulopathy or primary immune complex membranoproliferative glomerulonephritis","volume":"10","author":"Bomback","year":"2025","journal-title":"Kidney Int Rep"},{"issue":"10 suppl","key":"10.1053\/j.ajkd.2025.11.021_bib109","first-page":"SA","volume":"35","author":"Nester","year":"2024","journal-title":"J Am Soc Nephrol"},{"issue":"suppl 1","key":"10.1053\/j.ajkd.2025.11.021_bib110","first-page":"1011","article-title":"Clinical characteristics and outcomes of C3 glomerulopathy and immune complex MPGN from the UK National Registry of Rare Kidney Diseases (RaDaR)","volume":"39","author":"Masoud","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2025.11.021_bib111","article-title":"pharmacodynamic effects of ARO-C3, a subcutaneously administered investigational RNAi therapeutic targeting complement C3 in adult healthy volunteers","year":"2023","journal-title":"Arrowhead Pharmaceuticals"},{"issue":"11 suppl","key":"10.1053\/j.ajkd.2025.11.021_bib114","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1681\/ASN.20223311S1779a","article-title":"SYNERGY-1: a phase 1, first-in-human, safety, tolerability, immunogenicity, pharmacokinetics and pharmacodynamics study of KP104 in escalating single and multiple doses [abstract]","volume":"33","author":"Wabnitz","year":"2022","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2025.11.021_bib116","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.ymthe.2024.02.001","article-title":"C3d-targeted factor H inhibits tissue complement in disease models and reduces glomerular injury without affecting circulating complement","volume":"32","author":"Liu","year":"2024","journal-title":"Mol Ther"},{"issue":"suppl 3","key":"10.1053\/j.ajkd.2025.11.021_bib118","article-title":"Alternative pathway MASP-3 inhibitor OMS906: results from a first-in-man phase 1 study in healthy subjects and study design of two ongoing clinical trials in patients with PNH [abstract]","volume":"7","author":"Griffin","year":"2023","journal-title":"HemaSphere"},{"key":"10.1053\/j.ajkd.2025.11.021_bib120","article-title":"SanegeneBio announces the initiation of phase II clinical trials for the siRNA drug SGB-9768 targeting C3 mRNA","year":"2025","journal-title":"SanegeneBio"},{"issue":"5","key":"10.1053\/j.ajkd.2025.11.021_bib122","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1681\/ASN.2013070715","article-title":"Clinical findings, pathology, and outcomes of C3GN after kidney transplantation","volume":"25","author":"Zand","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2025.11.021_bib123","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.kint.2016.08.030","article-title":"Recent advances in our understanding of recurrent primary glomerulonephritis after kidney transplantation","volume":"91","author":"Cosio","year":"2017","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.ajkd.2025.11.021_bib124","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s40620-019-00672-5","article-title":"Outcome of C3 glomerulopathy patients: largest single-centre experience from South Asia","volume":"33","author":"Kumar","year":"2020","journal-title":"J Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2025.11.021_bib125","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2017.11.019","article-title":"Patterns of clinical response to eculizumab in patients with C3 glomerulopathy","volume":"72","author":"Le Quintrec","year":"2018","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1053\/j.ajkd.2025.11.021_bib126","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1053\/j.ajkd.2018.12.046","article-title":"C5 convertase blockade in membranoproliferative glomerulonephritis: a single-arm clinical trial","volume":"74","author":"Ruggenenti","year":"2019","journal-title":"Am J Kidney Dis"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638626008280?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638626008280?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T22:29:44Z","timestamp":1782512984000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638626008280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":120,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0272638626008280"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2025.11.021","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complement 3 Glomerulopathy (C3G) in Native and Posttransplant Kidneys: A Review","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2025.11.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}